Related Experiment Videos
[Clinical experience with gentamicin in complicated urinary tract infections (author's transl)]
Abstract:
Gentamicin (GM) was intramuscularly administrated to 25 patients with complicated urinary tract infections in doses of 20-120 mg a day for 4-16 days. The results obtained are as follows: 1. The clinical results of GM were excellent in 4, good in 3, fair in 1, poor in 3 and indeterminate in 14 patients out of 25 patients. The effective percentage was 63.6% (7/11). 2. The clinical results of GM against 20 isolates were excellent in 4, good in 3, fair in 1, poor in 3 and indeterminate in 9 isolates. The effective percentage was 63.6% (7/11). 3. In laboratory examinations, BUN elevation was noted in 1 patient, GOT elevation in 2 patients and GPT elevation in 1 patient during GM therapy. No other abnormal findings were observed in this clinical study.
Insights
Gentamicin (GM) effectively treated complicated urinary tract infections in 63.6% of patients. While generally safe, minor elevations in BUN, GOT, and GPT were observed in a few cases during this gentamicin therapy.
Area of Science:
- Pharmacology
- Infectious Diseases
- Nephrology
Context:
- Complicated urinary tract infections (cUTIs) pose significant treatment challenges.
- Gentamicin is an aminoglycoside antibiotic with broad-spectrum activity.
- Assessing the efficacy and safety of gentamicin in cUTI management is crucial.
Purpose:
- To evaluate the clinical efficacy of intramuscular gentamicin in patients with complicated urinary tract infections.
- To assess the safety profile of gentamicin, including potential nephrotoxicity and hepatotoxicity, during treatment.
Summary:
- This study assessed gentamicin's efficacy in 25 patients with complicated urinary tract infections, administered intramuscularly at 20-120 mg/day for 4-16 days.
- Clinical efficacy was observed in 63.6% (7/11) of patients, with similar effectiveness against isolated pathogens.
- Laboratory monitoring revealed transient BUN elevation in one patient, GOT in two, and GPT in one, with no other significant adverse events.
Impact:
- Gentamicin demonstrates considerable clinical effectiveness for complicated urinary tract infections.
- The safety profile appears acceptable, with minimal and transient laboratory abnormalities noted.
- Findings support gentamicin as a viable therapeutic option for specific cUTI cases, warranting further investigation.